Yi-Zhou Jiang
Co-architect of the Fudan TNBC subtypes and the metabolic and immune atlases that guide subtype-specific treatment.
Yi-Zhou Jiang led the multi-omic characterisation of Chinese triple-negative breast cancers, including metabolomic and immune subtyping, and co-leads the FUTURE trial series with Zhi-Ming Shao.
| Title | Journal | Year |
|---|---|---|
| Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies | Cancer Cell | 2019 |
Pages like this
not linked directly; found by shared links- PersonZhi-Ming Shao
Shares Fudan University Shanghai Cancer Center, RNA sequencing & expression profiling, Triple-negative breast cancer (TNBC).
- PersonXichun Hu
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
- PersonShaoli Song
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
- InstitutionEMBL's European Bioinformatics Institute
Shares Proteomics & phosphoproteomics, RNA sequencing & expression profiling.
- InstitutionSkåne University Hospital / Lund University Cancer Centre
Shares RNA sequencing & expression profiling, Triple-negative breast cancer (TNBC).
- InstitutionSOLTI Cancer Research Group
Shares RNA sequencing & expression profiling, Triple-negative breast cancer (TNBC).
- TermPAM50 / intrinsic subtypes
Shares RNA sequencing & expression profiling, Triple-negative breast cancer (TNBC).
- InstitutionInstitut Jules Bordet
Shares RNA sequencing & expression profiling, Triple-negative breast cancer (TNBC).